Sarepta Therapeutics (NASDAQ:SRPT) Given New $181.00 Price Target at Royal Bank of Canada

Sarepta Therapeutics (NASDAQ:SRPT) had its target price cut by Royal Bank of Canada from $182.00 to $181.00 in a research report sent to investors on Thursday, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

Several other equities analysts have also commented on SRPT. Citigroup lowered their target price on Sarepta Therapeutics from $176.00 to $160.00 and set a neutral rating for the company in a report on Thursday. Oppenheimer raised Sarepta Therapeutics from a market perform rating to an outperform rating and set a $180.00 target price for the company in a report on Tuesday, May 14th. Robert W. Baird increased their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an outperform rating in a report on Friday, June 21st. Mizuho increased their price objective on Sarepta Therapeutics from $145.00 to $179.00 and gave the stock a buy rating in a report on Friday, May 17th. Finally, Evercore ISI raised Sarepta Therapeutics from an in-line rating to an outperform rating and decreased their price objective for the stock from $185.00 to $179.00 in a report on Thursday. Three research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics has a consensus rating of Moderate Buy and an average target price of $186.22.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT traded down $11.06 during trading on Thursday, reaching $125.34. 3,303,443 shares of the company’s stock traded hands, compared to its average volume of 1,396,233. The stock has a market capitalization of $11.85 billion, a P/E ratio of 1,139.45 and a beta of 0.89. Sarepta Therapeutics has a 12 month low of $55.25 and a 12 month high of $173.25. The company has a 50 day moving average of $141.00 and a 200-day moving average of $131.41. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter. The company had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The business’s revenue was up 38.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.27) earnings per share. On average, equities analysts expect that Sarepta Therapeutics will post 3.76 EPS for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In other news, insider Bilal Arif sold 7,859 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the completion of the sale, the insider now owns 21,261 shares in the company, valued at approximately $3,467,243.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Bilal Arif sold 7,859 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the completion of the sale, the insider now owns 21,261 shares in the company, valued at approximately $3,467,243.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Ryan Edward Brown sold 38,957 shares of the stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total value of $6,295,840.77. Following the sale, the executive vice president now owns 17,129 shares of the company’s stock, valued at approximately $2,768,217.69. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SRPT. International Assets Investment Management LLC raised its holdings in shares of Sarepta Therapeutics by 9,382.5% during the fourth quarter. International Assets Investment Management LLC now owns 11,379 shares of the biotechnology company’s stock worth $1,097,000 after acquiring an additional 11,259 shares in the last quarter. Sapient Capital LLC acquired a new position in Sarepta Therapeutics during the fourth quarter worth $978,000. WCM Investment Management LLC acquired a new position in Sarepta Therapeutics during the fourth quarter worth $600,000. Vontobel Holding Ltd. increased its position in Sarepta Therapeutics by 12.8% during the fourth quarter. Vontobel Holding Ltd. now owns 25,278 shares of the biotechnology company’s stock worth $2,438,000 after buying an additional 2,863 shares during the last quarter. Finally, abrdn plc acquired a new position in Sarepta Therapeutics during the fourth quarter worth $14,159,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.